Corporate Development

Corporate Development

Jazz has a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. We work to expand the science behind our medicines, acquire new therapies that will make a difference in patients’ lives, and partner to develop early-stage or later-stage molecules with great potential – reaffirming our commitment to patients with each decision. We seek solutions for rare or complex diseases, and we help ensure those solutions are available for the often-overlooked patients who need them.

Our Approach

Our integrated approach allows us to effectively evaluate opportunities, spanning from pre-clinical to commercial products. We have a team of experienced leaders with a demonstrated history of successful deals and partnerships, and we have significant capital available for deployment. Finally, our operational expertise and scale advantages us to support development, regulatory and commercial success.

Facts & Figures


  • We acquired and made available the first FDA-approved treatment for narcolepsy with cataplexy – a life-long disorder causing excessive sleepiness and muscle weakness; and continue to focus on development of options for narcolepsy patients with excessive sleepiness.

Hematology and Oncology

  • We developed the first new treatment in more than 40 years for adults with two types of high-risk acute myeloid leukemia (AML);
  • For patients with acute lymphoblastic leukemia (ALL), we launched the first solution for those who have developed hypersensitivity to E. coli-derived asparaginase – a severe reaction to other therapies; and
  • We introduced the only option on the market for helping both adults and children recover from rare, life-threatening complication of stem cell transplants.

Areas of Interest

  • Hematology and oncology + adjacencies
  • Neuroscience
  • Sleep + adjacencies
  • Other therapeutic areas

Contact Corporate Development & Partnering